Signalling input from divergent pathways subverts B cell transformation.
Animals
B-Lymphocytes
/ cytology
Cell Line, Tumor
Cell Transformation, Neoplastic
Enzyme Activation
Extracellular Signal-Regulated MAP Kinases
/ metabolism
Female
Humans
Leukemia, B-Cell
/ metabolism
Mice
Protein Tyrosine Phosphatase, Non-Receptor Type 6
/ metabolism
Proto-Oncogene Proteins c-bcl-6
/ metabolism
Proto-Oncogene Proteins c-myc
/ metabolism
STAT5 Transcription Factor
/ metabolism
Signal Transduction
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
04
06
2019
accepted:
28
04
2020
pubmed:
24
7
2020
medline:
12
1
2021
entrez:
24
7
2020
Statut:
ppublish
Résumé
Malignant transformation of cells typically involves several genetic lesions, whose combined activity gives rise to cancer
Identifiants
pubmed: 32699415
doi: 10.1038/s41586-020-2513-4
pii: 10.1038/s41586-020-2513-4
pmc: PMC7394729
mid: NIHMS1589127
doi:
Substances chimiques
BCL6 protein, human
0
Proto-Oncogene Proteins c-bcl-6
0
Proto-Oncogene Proteins c-myc
0
STAT5 Transcription Factor
0
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
PTPN6 protein, human
EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 6
EC 3.1.3.48
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
845-851Subventions
Organisme : NCI NIH HHS
ID : R00 CA197498
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157644
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA233412
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197628
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA212252
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA233691
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA231958
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA236626
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213138
Pays : United States
Références
Fearon, E. R., Hamilton, S. R. & Vogelstein, B. Clonal analysis of human colorectal tumors. Science 238, 193–197 (1987).
doi: 10.1126/science.2889267
Goetz, C. A., Harmon, I. R., O’Neil, J. J., Burchill, M. A. & Farrar, M. A. STAT5 activation underlies IL7 receptor-dependent B cell development. J. Immunol. 172, 4770–4778 (2004).
doi: 10.4049/jimmunol.172.8.4770
Malin, S. et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat. Immunol. 11, 171–179 (2010).
doi: 10.1038/ni.1827
Katerndahl, C. D. S. et al. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat. Immunol. 18, 694–704 (2017).
doi: 10.1038/ni.3716
Shaw, A. C., Swat, W., Ferrini, R., Davidson, L. & Alt, F. W. Activated Ras signals developmental progression of recombinase-activating gene (RAG)-deficient pro-B lymphocytes. J. Exp. Med. 189, 123–129 (1999).
doi: 10.1084/jem.189.1.123
Irving, J. et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 124, 3420–3430 (2014).
doi: 10.1182/blood-2014-04-531871
Anderson, L. J. & Longnecker, R. EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway. J. Gen. Virol. 89, 1563–1568 (2008).
doi: 10.1099/vir.0.2008/001461-0
Feldhahn, N. et al. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J. Exp. Med. 201, 1837–1852 (2005).
doi: 10.1084/jem.20042101
Yasuda, T. et al. Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity 28, 499–508 (2008).
doi: 10.1016/j.immuni.2008.02.015
Shojaee, S. et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat. Med. 22, 379–387 (2016).
doi: 10.1038/nm.4062
Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018).
doi: 10.1126/science.aau3879
Mandal, M. et al. Ras orchestrates exit from the cell cycle and light-chain recombination during early B cell development. Nat. Immunol. 10, 1110–1117 (2009).
doi: 10.1038/ni.1785
Duy, C. et al. BCL6 is critical for the development of a diverse primary B cell repertoire. J. Exp. Med. 207, 1209–1221 (2010).
doi: 10.1084/jem.20091299
Geng, H. et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell 27, 409–425 (2015).
doi: 10.1016/j.ccell.2015.02.003
Swaminathan, S. et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat. Immunol. 16, 766–774 (2015).
doi: 10.1038/ni.3160
Walker, S. R. et al. STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol. Cell. Biol. 33, 2879–2890 (2013).
doi: 10.1128/MCB.01620-12
Korotchenko, V. N. et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. ChemBioChem 15, 1436–1445 (2014).
doi: 10.1002/cbic.201402000
Shojaee, S. et al. Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell 28, 114–128 (2015).
doi: 10.1016/j.ccell.2015.05.008
Yang, J. et al. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem. Biol. 18, 177–186 (2011).
doi: 10.1016/j.chembiol.2010.12.013
Heltemes-Harris, L. M. et al. Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia. Oncogene 35, 3454–3464 (2016).
doi: 10.1038/onc.2015.405
Porpaczy, E. et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 132, 694–706 (2018).
doi: 10.1182/blood-2017-10-810739
Xiao, W. et al. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell 16, 161–171 (2009).
doi: 10.1016/j.ccr.2009.05.018
Fusaki, N. et al. BLNK is associated with the CD72/SHP-1/Grb2 complex in the WEHI231 cell line after membrane IgM cross-linking. Eur. J. Immunol. 30, 1326–1330 (2000).
doi: 10.1002/(SICI)1521-4141(200005)30:5<1326::AID-IMMU1326>3.0.CO;2-Q
Imamura, Y. et al. BLNK binds active H-Ras to promote B cell receptor-mediated capping and ERK activation. J. Biol. Chem. 284, 9804–9813 (2009).
doi: 10.1074/jbc.M809051200
Nikolaev, S. I. et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat. Commun. 5, 4654 (2014).
doi: 10.1038/ncomms5654
Herold, T. et al. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica 102, 130–138 (2017).
doi: 10.3324/haematol.2015.136366
Jerchel, I. S. et al. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. Leukemia 32, 931–940 (2018).
doi: 10.1038/leu.2017.303
Cerami, E. et al. The cBio Cancer Genomics Portal: An opening platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
doi: 10.1158/2159-8290.CD-12-0095
Koch, R. et al. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood 133, 566–575 (2019).
doi: 10.1182/blood-2018-07-865527
Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585–615 (1939).
doi: 10.1111/j.1744-7348.1939.tb06990.x
Weibull, W. A statistical distribution function of wide applicability. J. Appl. Mech. 18, 293–297 (1951).
R Development Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna (2009).